Summit Trail Advisors’s Tvardi Therapeutics TVRD Stock Holding History

Summit Trail Advisors’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1	Closed	–	–	1721
2017 Q4	$0	Buy	+1	New	+$456	﹤0.01%	2109

Other funds holding TVRD

RCP

Rho Capital Partners New York $20.4M AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

Summit Trail Advisors's TVRD Position: Q1 2018 in Review

Summit Trail Advisors sold out of Tvardi Therapeutics (TVRD) in Q1 2018, closing a stake of 1 share.

Summit Trail Advisors first reported a position in TVRD in Q4 2017 and held it in 1 quarter. The position peaked at $0 in Q4 2017. 121 funds tracked by Wall St. Rank hold TVRD as of Q1 2018.

Summit Trail Advisors reported no remaining Tvardi Therapeutics position as of Q1 2018 after selling out during the quarter.
Summit Trail Advisors sold 1 Tvardi Therapeutics share in Q1 2018.
Summit Trail Advisors first reported a position in Tvardi Therapeutics in Q4 2017 and held it in 1 quarter.
Summit Trail Advisors's Tvardi Therapeutics position peaked at $0 in Q4 2017.
121 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2018.

Based on Summit Trail Advisors's 13F filing for Q1 2018, filed 21 May 2018.